Tests and monitoring

The Phase 2b results suggest the investigational TL1A drug duvakitug improved clinical and endoscopic outcomes versus placebo in both ulcerative colitis and Crohn’s disease, which could expand future treatment options if...

If approved, Tremfya SC induction could provide a fully subcutaneous induction and maintenance option for people with moderately to severely active ulcerative colitis, which may be more convenient than IV induction.

This press release reports phase 2 evidence that a new experimental antibody (duvakitug) showed clinical, endoscopic, and histologic improvements in both UC and Crohn’s disease, which could lead to a new treatment option...

A new antibody, duvakitug, showed higher remission/response rates than placebo in Phase 2b study data for both ulcerative colitis and Crohn’s disease, which could lead to a new treatment option if Phase 3 trials confirm...

People with Crohn's disease who have an ileostomy need reliable, noninvasive tools to monitor for postoperative small-bowel inflammation. This study suggests fecal calprotectin measured from ileostomy output may help...

This study maps what researchers have been publishing about Crohn's disease in children over the past decade, highlighting major topics, influential papers, and active authors/institutions.

New oral TYK2 inhibitor data show promise on endoscopic healing and inflammatory markers in Crohn’s disease, which is important because oral treatment options are limited. However, the trial missed its main symptom-based...

Arthralgia and other extraintestinal symptoms may signal higher risk of developing peripheral arthritis in people with Crohn disease. Recognizing early joint pain could prompt closer monitoring or earlier rheumatology...

Faecal calprotectin from ileostomy output could provide a non-invasive way to detect small-bowel inflammation after surgery, helping to guide monitoring and reduce reliance on invasive tests for postoperative Crohn’s...

Cure8 found this source from onlinelibrary.wiley.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Fecal calprotectin. Open the original article for the...

Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Tests and monitoring. Open the original article...

Longer-term data help patients and clinicians understand whether an initial response to a new biologic (mirikizumab) is likely to last and whether safety findings remain acceptable over two years.

A validated AI biomarker that predicts which IBD treatments are likely to work could reduce trial-and-error in treatment choices, potentially shortening time to effective therapy for people with Crohn's disease or...

People with Crohn’s disease who have an ileostomy have limited noninvasive ways to monitor small-bowel inflammation. This study suggests measuring fecal calprotectin from ileostomy output could help detect postoperative...

Longer-term (two-year) results suggest mirikizumab (Omvoh) can maintain clinical and endoscopic benefits for many people with Crohn’s disease, including some with prior biologic failure, which is important when weighing...

This study suggests a common genetic marker (HLA‑DQA1*05) may help explain why some children stop responding to anti‑TNF drugs and could eventually guide who might benefit from adding methotrexate or closer monitoring.

Long-term maintenance of clinical and endoscopic remission is a key goal in Crohn’s disease care. Positive two-year data and FDA approval may affect treatment options for adults, including people who previously failed...

These are multi‑year clinical results for a newly approved IL‑23p19 inhibitor (mirikizumab) showing sustained clinical and endoscopic benefit for many patients with moderate‑to‑severe Crohn’s disease, including some who...

A noninvasive wearable that tracks inflammation markers could let people with IBD and their clinicians detect rising disease activity earlier and potentially act before symptoms develop. This may make monitoring less...

Vulvar Crohn’s is an uncommon but real extraintestinal manifestation that can cause painful skin changes and sometimes appears before GI Crohn’s is diagnosed. Knowing about it may speed diagnosis and lead to coordinated...

Long-term data matter because they show whether benefits and safety of a new biologic hold up beyond the initial trial period. For people with Crohn’s disease, sustained clinical remission and endoscopic healing are...

This press release reports multi-year data suggesting many patients treated continuously with mirikizumab maintained clinical remission and endoscopic response at two years—outcomes people with Crohn’s disease often care...

A new VEGFR2-targeted ultrasound contrast (BR55) has FDA fast track status for imaging active Crohn’s inflammation, which could eventually offer a non‑invasive way to monitor disease activity and treatment response...

This agent is being developed as a targeted, radiation-free ultrasound contrast to detect active bowel inflammation and angiogenesis in Crohn’s disease, which could improve non-invasive monitoring of disease activity and...

This press release reports multi-year clinical trial data suggesting sustained remission and intestinal healing with Omvoh (mirikizumab) in patients with Crohn's disease—information that could affect treatment...

This roundup highlights new IBD research and real-world care issues that could influence future diagnosis, monitoring, and access to treatments. Findings on financial barriers and gaps in treat-to-target monitoring may...

This trial suggests a new IL‑23 inhibitor, mirikizumab, may be an effective and safe treatment option for adults with moderate-to-severe Crohn's disease who have not responded to prior therapies. Positive phase 3 results...

The article summarizes recent drug approvals and Phase 3 trial results that could affect which biologic treatments are available and how the Crohn's disease treatment market may change. It also gives epidemiology and...

Knowing the type of Crohn’s disease helps explain where symptoms come from and what treatments or procedures might be considered. The article links specific symptoms and complications to each anatomical pattern of...

A test that more accurately predicts which IBD patients with pre-cancerous bowel changes will develop cancer could help target surveillance and treatment to those at higher risk and reduce unnecessary procedures for...

Based on the title and source metadata, this appears to be a biomarker study related to Colorectal cancer and Tests and monitoring. The original article is from msn.com.

Based on the title and source metadata, this appears to be a patient education related to Tests and monitoring. The original article is from msn.com.

Cure8 found this source from newsx.com, but the page could not be read reliably yet. It is tagged for Colorectal Cancer Risk and Tests and monitoring. Open the original article for the full details.

The article spotlights duvakitug and the anti‑TL1A drug class as potential new options for ulcerative colitis and Crohn’s disease, especially for treatment‑experienced patients. Biomarker‑driven studies could help...

This article reports positive trial results for ustekinumab, a drug that targets IL-12 and IL-23, showing benefit in people with Crohn's disease who did not respond to anti‑TNF drugs. That could expand options for...

This paper highlights potential ubiquitination-related genes and immune-cell patterns that could help researchers understand Crohn’s disease biology and point to new targets for lab validation. For patients, it signals...

Skin patches and other non‑digestive symptoms can be part of Crohn's disease and may prompt further evaluation. Knowing these signs could help people seek earlier assessment from a GP.

Researchers are trying to find blood biomarkers and a risk score that could predict who will develop Crohn’s disease before symptoms appear, which might enable earlier interventions or prevention in the future.

People with celiac disease may have higher risks for several digestive cancers and for inflammatory bowel diseases (Crohn’s and UC) according to this large French cohort study. Knowing these associations can help...

If successful, validated biomarkers and a blood risk score could allow clinicians to identify people at high risk of developing Crohn's disease and eventually test interventions to prevent symptoms. Prevention-focused...

Anal fistulas are a common and often painful complication of Crohn’s disease that usually need medical or surgical treatment. Managing the underlying Crohn’s with biologic therapy is often necessary for fistulas to heal....

This study links a specific SERPINB4 gene mutation to impaired intestinal epithelial cell function in twins with Crohn’s disease, which could help explain how rare genetic variants contribute to disease in some patients.

Understanding the differences between Crohn’s and ulcerative colitis helps patients and caregivers recognize likely symptom patterns, know which tests and treatments are commonly used, and when to seek specialist care....

Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Medications. Open the original article for the full details.

This announces a new FDA‑approved treatment (mirikizumab/Omvoh) for adults with moderately to severely active Crohn disease, offering another option for people who haven’t responded to prior therapies. The approval was...

A new FDA-approved biologic (Omvoh/mirikizumab) gives adults with moderate-to-severe Crohn disease another treatment option with one-year trial data showing improved clinical remission and endoscopic healing versus...

This gives adults with moderately to severely active Crohn’s disease an additional FDA-approved biologic option that targets the IL-23 pathway. Approval was supported by late-stage trial results showing improvements in...

At‑home tests that claim to identify food triggers for IBS or related gut conditions may influence how people manage symptoms. Patents covering tests for Crohn’s and ulcerative colitis suggest the company is aiming to...